ADVOCATE. CONNECT. INNOVATE.

Fellows

Decoy Biosystems

Organization Address
JLABS / Decoy Biosystems
Att: Michael Newman
3210 Merryfield Row
San Diego, CA 92121

Organization Phone
Office 1-858-242-1578 / Mobile 1-858-922-9015

Industry
Biotech and Pharmaceutical

Organization Description

Decoy Biosystems is a private, San Diego-based, biotechnology company developing a novel and potentially best in class multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy. Our approach utilizes killed, non-pathogenic bacteria, which act as a “decoy” to attract immune cells and activate an anti-tumor immune response. Unlike competitor TLR agonist-associated products, Decoy’s patented technology does not depend on targeting to a specific tumor antigen or use of a locally administered therapy to try to induce an immune response against distant, metastatic disease. Decoy’s intravenously administered drug candidates can safely eradicate established lymphoma, hepatocellular and colorectal tumors in standard preclinical models and are also active in a metastatic pancreatic carcinoma model. Decoy therapy eradicates tumors via both innate and adaptive immune mechanisms and induces immunological memory, producing resistance to subsequent tumor challenge. Decoy’s first product will enter clinical development in 2020, targeting tumors that do not exhibit durable responses or exhibit low durable response rates to current immunotherapy.